Abstract
Introduction
Screening for increased levels of prostate-specific antigen (PSA) has allowed early detection of a large majority of prostate cancer (PCa) cases. However, the relative lack of specificity of PSA has resulted in significant over-diagnosis and unnecessary treatment for indolent tumors. The fusion of the transmembrane protease serine 2 with E26 transformation-specific family genes, particularly ERG, is the most widespread genetic alteration in prostate cancer, and data suggest that it is more specific for neoplastic prostate disease and may be of added prognostic value and point toward molecular subtype of PCa.
Methods
In this review, retrospective studies and clinical trials were analyzed to highlight the recent advances in our understanding of the cellular consequence of ERG rearrangement, describe its interactions with other genetic and molecular pathways, and discuss its potential diagnostic and prognostic value.
Conclusion
ERG over-expression has an emerging role in the diagnosis of PCa pathology, although there is still debate about its prognostic value. Elucidation of the mechanisms of ERG gene rearrangements and expression promises novel therapeutic and diagnostic avenues for prostate cancer.
Similar content being viewed by others
References
Al Bashir S, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA (2014) Cysteine-rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients’ prognosis. J Hematol Oncol 7:21. doi:10.1186/1756-8722-7-21
Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X et al (2011) Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 3(72):72ra17. doi:10.1126/scitranslmed.3001498
Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P et al (2008) Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27(3):253–263. doi:10.1038/sj.onc.1210640
Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR (2000) Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60(16):4629–4637
Badawi AF (2000) The role of prostaglandin synthesis in prostate cancer. BJU Int 85(4):451–462
Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y et al (2013) ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 27(6):683–698. doi:10.1101/gad.211011.112
Barfeld SJ, East P, Zuber V, Mills IG (2014) Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. BMC Med Genomics 7(1):513. doi:10.1186/s12920-014-0074-9
Berg KD, Vainer B, Thomsen FB, Roder MA, Gerds TA, Toft BG et al (2014) ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol 66(5):851–860. doi:10.1016/j.eururo.2014.02.058
Bettendorf O, Schmidt H, Staebler A, Grobholz R, Heinecke A, Boecker W et al (2008) Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. Genes Chromosomes Cancer 47(7):565–572
Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J et al (2011) PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 107(3):477–485. doi:10.1111/j.1464-410X.2010.09470.x
Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA (2012a) Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology 60(4):645–652. doi:10.1111/j.1365-2559.2011.04116.x
Bismar TA, Dolph M, Teng LH, Liu S, Donnelly B (2012b) ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. Eur J Cancer 48(4):538–546. doi:10.1016/j.ejca.2012.01.001
Bismar TA, Alshalalfa M, Petersen LF, Teng LH, Gerke T, Bakkar A et al (2014) Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients’ clinical outcome. BJU Int 113(2):309–319. doi:10.1111/bju.12262
Boormans JL, Hermans KG, Made AC, van Leenders GJ, Wildhagen MF, Collette L et al (2010) Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naive, node-positive prostate cancer. Eur Urol 57(5):830–835. doi:10.1016/j.eururo.2009.08.013
Brase JC, Johannes M, Mannsperger H, Falth M, Metzger J, Kacprzyk LA et al (2011) TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 11:507. doi:10.1186/1471-2407-11-507
Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA et al (2011) Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19(5):664–678. doi:10.1016/j.ccr.2011.04.010
Burdova A, Bouchal J, Tavandzis S, Kolar Z (2014) TMPRSS2-ERG gene fusion in prostate cancer. Biomed Pap 158(4):502–510. doi:10.5507/bp.2014.065
Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A et al (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41(5):619–624. doi:10.1038/ng.370
Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA et al (2011) Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 35(7):1014–1020. doi:10.1097/PAS.0b013e31821e8761
Chen H, Nandi AK, Li X, Bieberich CJ (2002) NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res 62(2):338–340
Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS et al (2007) Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26(18):2667–2673. doi:10.1038/sj.onc.1210070
Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A et al (2013) TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res 19(18):5202–5209. doi:10.1158/1078-0432.CCR-13-1049
Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA (2009) TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther 8(2):125–130
Dasgupta S, Srinidhi S, Vishwanatha JK (2012) Oncogenic activation in prostate cancer progression and metastasis: molecular insights and future challenges. J Carcinog 11:4. doi:10.4103/1477-3163.93001
Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR et al (2007) TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31):4596–4599. doi:10.1038/sj.onc.1210237
Denmeade SR, Isaacs JT (2002) A history of prostate cancer treatment. Nat Rev Cancer 2(5):389–396. doi:10.1038/nrc801
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R et al (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101(6):374–383. doi:10.1093/jnci/djp001
Duterque-Coquillaud M, Niel C, Plaza S, Stehelin D (1993) New human erg isoforms generated by alternative splicing are transcriptional activators. Oncogene 8(7):1865–1873
Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M et al (2010) ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol 23(11):1499–1506. doi:10.1038/modpathol.2010.150
Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1):34–45. doi:10.1038/35094009
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403. doi:10.1016/j.ejca.2012.12.027
Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E et al (2014) Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer Epidemiol Biomarkers Prev 23(4):594–600. doi:10.1158/1055-9965.EPI-13-1180
Franco OE, Hayward SW (2012) Targeting the tumor stroma as a novel therapeutic approach for prostate cancer. Adv Pharmacol 65:267–313. doi:10.1016/B978-0-12-397927-8.00009-9
Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA et al (2010) ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 13(3):228–237. doi:10.1038/pcan.2010.23
Gasi Tandefelt D, Boormans JL, van der Korput HA, Jenster GW, Trapman J (2013) A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers. Eur Urol 64(6):941–950. doi:10.1016/j.eururo.2013.02.039
Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C, Sugar L et al (2011) miR-221 is down-regulated in TMPRSS2: ERG fusion-positive prostate cancer. Anticancer Res 31(2):403–410
Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A et al (2013a) Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod Pathol 26(5):733–742. doi:10.1038/modpathol.2012.206
Grupp K, Diebel F, Sirma H, Simon R, Breitmeyer K, Steurer S et al (2013b) SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. Prostate 73(15):1690–1698. doi:10.1002/pros.22707
Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P et al (2011) TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 42(1):11–17. doi:10.1016/j.humpath.2010.05.026
Hagglof C, Hammarsten P, Stromvall K, Egevad L, Josefsson A, Stattin P et al (2014) TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS One 9(2):e86824. doi:10.1371/journal.pone.0086824
Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR et al (2008) Characterization of TMPRSS2:ETV5 and SLC45A3: ETV5 gene fusions in prostate cancer. Cancer Res 68(1):73–80
Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J (2006) TMPRSS2: ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66(22):10658–10663. doi:10.1158/0008-5472.CAN-06-1871
Hermans KG, van der Korput HA, van Marion R, van de Wijngaart DJ, Ziel-van der Made A, Dits NF et al (2008) Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res 68(18):7541–7549. doi:10.1158/0008-5472.CAN-07-5930
Hollenhorst PC, McIntosh LP, Graves BJ (2011) Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 80:437–471. doi:10.1146/annurev.biochem.79.081507.103945
Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ et al (2012) ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 25(3):471–479. doi:10.1038/modpathol.2011.176
Huang KC, Dolph M, Donnelly B, Bismar TA (2014) ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer. Clin Transl Oncol 16(11):973–979. doi:10.1007/s12094-014-1182-x
Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI et al (2006) TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66(21):10242–10246
Kanazawa T, Ogawa C, Taketani T, Taki T, Hayashi Y, Morikawa A (2005) TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease. Leuk Lymphoma 46(12):1833–1835. doi:10.1080/10428190500162203
Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW et al (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7(4):437–443. doi:10.1038/86507
King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH et al (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41(5):524–526
Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD et al (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105(6):2105–2110. doi:10.1073/pnas.0711711105
Kron K, Trudel D, Pethe V, Briollais L, Fleshner N, van der Kwast T et al (2013) Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clin Cancer Res 19(13):3450–3461. doi:10.1158/1078-0432.CCR-12-3139
Kumar-Sinha C, Tomlins SA, Chinnaiyan AM (2008) Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8(7):497–511. doi:10.1038/nrc2402
Lee SL, Yu D, Wang C, Saba R, Liu S, Trpkov K et al (2014) ERG expression in prostate needle biopsy: potential diagnostic and prognostic implications. Appl Immunohistochem Mol Morphol. doi:10.1097/PAI.0000000000000119
Lee SL, Yu D, Wang C, Saba R, Liu S, Trpkov K et al (2015) ERG expression in prostate needle biopsy: potential diagnostic and prognostic implications. Appl Immunohistochem Mol Morphol 23(7):499–505. doi:10.1097/PAI.0000000000000119
Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramaki OR et al (2010) Association of SPINK1 expression and TMPRSS2: ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 16(10):2845–2851. doi:10.1158/1078-0432.CCR-09-2505
Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S et al (2013) Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev 22(12):2333–2344. doi:10.1158/1055-9965.epi-13-0333-t
Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB et al (2014) Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 65(3):534–542. doi:10.1016/j.eururo.2012.11.014
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943–1947
Liu S, Yoshimoto M, Trpkov K, Duan Q, Firszt M, Corcos J et al (2011) Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone. Cancer Biol Ther 11(6):562–566
Locke JA, Zafarana G, Ishkanian AS, Milosevic M, Thoms J, Have CL et al (2012) NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clin Cancer Res 18(1):308–316. doi:10.1158/1078-0432.CCR-11-2147
Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A et al (2011) ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 24(6):820–828. doi:10.1038/modpathol.2011.7
Loughran SJ, Kruse EA, Hacking DF, de Graaf CA, Hyland CD, Willson TA et al (2008) The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol 9(7):810–819. doi:10.1038/ni.1617
Mahdian R, Nodouzi V, Asgari M, Rezaie M, Alizadeh J, Yousefi B et al (2014) Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer. Mol Biol Rep 41(9):6125–6131. doi:10.1007/s11033-014-3491-0
Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S et al (2009) Induced chromosomal proximity and gene fusions in prostate cancer. Science 326(5957):1230. doi:10.1126/science.1178124
Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT et al (2007) Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20(5):538–544. doi:10.1038/modpathol.3800769
Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S et al (2007) Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 9(3):200–206
Miettinen M, Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S et al (2011) ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 35(3):432–441. doi:10.1097/PAS.0b013e318206b67b
Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS et al (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 17(18):5878–5888. doi:10.1158/1078-0432.CCR-11-1251
Mochmann LH, Neumann M, von der Heide EK, Nowak V, Kuhl AA, Ortiz-Tanchez J et al (2014) ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells. Oncotarget 5(2):351–362
Mohamed AA, Tan SH, Sun C, Shaheduzzaman S, Hu Y, Petrovics G et al (2011) ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther 11(4):410–417
Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD et al (2008) Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 14(11):3380–3385. doi:10.1158/1078-0432.CCR-07-5194
Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446(7137):758–764. doi:10.1038/nature05690
Nagle RB, Algotar AM, Cortez CC, Smith K, Jones C, Sathyanarayana UG et al (2013) ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma. Prostate 73(11):1233–1240. doi:10.1002/pros.22675
Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH et al (2007a) Expression of TMPRSS2: ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 6(1):40–45
Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY et al (2007b) Expression of the TMPRSS2: ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97(12):1690–1695
Ng HH, Bird A (2000) Histone deacetylases: silencers for hire. Trends Biochem Sci 25(3):121–126
Oh SH, Park TS, Choi JR, Lee S, Cho SY, Kim SY et al (2010) Two childhood cases of acute leukemia with t(16;21)(p11.2;q22): second case report of infantile acute lymphoblastic leukemia with unusual type of FUS-ERG chimeric transcript. Cancer Genet Cytogenet 200(2):180–183. doi:10.1016/j.cancergencyto.2010.04.009
Owczarek CM, Portbury KJ, Hardy MP, O’Leary DA, Kudoh J, Shibuya K et al (2004) Detailed mapping of the ERG–ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. Gene 324:65–77
Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R et al (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12(7):590–598
Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG et al (2014) TMPRSS2: ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol 32(3):206–211. doi:10.1200/JCO.2013.49.8386
Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S et al (2006) TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66(17):8337–8341
Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y et al (2005) Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24(23):3847–3852. doi:10.1038/sj.onc.1208518
Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA et al (2009) N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 11(8):804–811
Rajan P, Stockley J, Sudbery IM, Fleming JT, Hedley A, Kalna G et al (2014) Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. BMC Cancer 14:977. doi:10.1186/1471-2407-14-977
Rao VN, Papas TS, Reddy ES (1987) erg, a human ets-related gene on chromosome 21: alternative splicing, polyadenylation, and translation. Science 237(4815):635–639
Rao VN, Modi WS, Drabkin HD, Patterson D, O’Brien SJ, Papas TS et al (1988) The human erg gene maps to chromosome 21, band q22: relationship to the 8; 21 translocation of acute myelogenous leukemia. Oncogene 3(5):497–500
Reddy ES, Rao VN, Papas TS (1987) The erg gene: a human gene related to the ets oncogene. Proc Natl Acad Sci U S A 84(17):6131–6135
Ribeiro FR, Paulo P, Costa VL, Barros-Silva JD, Ramalho-Carvalho J, Jeronimo C et al (2011) Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One 6(7):e22317. doi:10.1371/journal.pone.0022317
Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1(1):19–25. doi:10.1016/j.molonc.2007.01.001
Ross LE, Berkowitz Z, Ekwueme DU (2008) Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology 17(3):636–644. doi:10.1158/1055-9965.EPI-07-2709
Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S et al (2008) Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100(11):815–825. doi:10.1093/jnci/djn150
Shah RB (2013) Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management. Adv Anat Pathol 20(2):117–124. doi:10.1097/PAP.0b013e3182862ac5
Shah RB, Tadros Y, Brummell B, Zhou M (2013) The diagnostic use of ERG in resolving an “atypical glands suspicious for cancer” diagnosis in prostate biopsies beyond that provided by basal cell and alpha-methylacyl-CoA-racemase markers. Hum Pathol 44(5):786–794. doi:10.1016/j.humpath.2012.06.024
Sharrocks AD (2001) The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2(11):827–837. doi:10.1038/35099076
Shimizu K, Ichikawa H, Tojo A, Kaneko Y, Maseki N, Hayashi Y et al (1993) An ets-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc Natl Acad Sci U S A 90(21):10280–10284
Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29. doi:10.3322/caac.21254
Slovin SF, Kelly WK, Wilton A, Kattan M, Myskowski P, Mendelsohn J et al (2009) Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 7(3):E77–E82. doi:10.3816/CGC.2009.n.028
Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT (1994) A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6(2):146–151. doi:10.1038/ng0294-146
Spencer ES, Johnston RB, Gordon RR, Lucas JM, Ussakli CH, Hurtado-Coll A et al (2013) Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality. Prostate 73(9):905–912. doi:10.1002/pros.22636
Steurer S, Mayer PS, Adam M, Krohn A, Koop C, Ospina-Klinck D et al (2014) TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. Eur Urol 66(6):978–981. doi:10.1016/j.eururo.2014.06.027
Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B et al (2008) TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27(40):5348–5353. doi:10.1038/onc.2008.183
Svensson MA, Perner S, Ohlson AL, Day JR, Groskopf J, Kirsten R et al (2014) A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort. Appl Immunohistochem Mol Morphol 22(2):136–141. doi:10.1097/PDM.0b013e31829e0484
Teng LH, Wang C, Dolph M, Donnelly B, Bismar TA (2013) ERG protein expression is of limited prognostic value in men with localized prostate cancer. ISRN Urol 2013:786545. doi:10.1155/2013/786545
Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maille P et al (2015) Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer. Cancer. doi:10.1002/cncr.29233
Thangapazham R, Saenz F, Katta S, Mohamed AA, Tan SH, Petrovics G et al (2014) Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. BMC Cancer 14:16. doi:10.1186/1471-2407-14-16
Tian TV, Tomavo N, Huot L, Flourens A, Bonnelye E, Flajollet S et al (2014) Identification of novel TMPRSS2: ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2. Oncogene 33(17):2204–2214. doi:10.1038/onc.2013.176
Tidehag V, Hammarsten P, Egevad L, Granfors T, Stattin P, Leanderson T et al (2014) High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome. Eur J Cancer 50(10):1829–1835. doi:10.1016/j.ejca.2014.03.278
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648
Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S et al (2015a) Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol 68(4):555–567. doi:10.1016/j.eururo.2015.04.033
Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP et al (2015b) Urine TMPRSS2: ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol. doi:10.1016/j.eururo.2015.04.039
Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC et al (2011) Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol 24(11):1511–1520. doi:10.1038/modpathol.2011.111
van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B et al (2011) Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 24(8):1128–1138. doi:10.1038/modpathol.2011.65
Wang J, Cai Y, Ren C, Ittmann M (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66(17):8347–8351. doi:10.1158/0008-5472.CAN-06-1966
Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M (2008) Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 68(20):8516–8524. doi:10.1158/0008-5472.CAN-08-1147
Wang JJ, Liu YX, Wang W, Yan W, Zheng YP, Qiao LD et al (2012) Fusion between TMPRSS2 and ETS family members (ERG, ETV1, ETV4) in prostate cancers from northern China. Asian Pac J Cancer Prev 13(10):4935–4938
Wilson S, Greer B, Hooper J, Zijlstra A, Walker B, Quigley J et al (2005) The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J 388(Pt 3):967–972. doi:10.1042/BJ20041066
Yaskiv O, Zhang X, Simmerman K, Daly T, He H, Falzarano S et al (2011) The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol 35(7):1062–1068. doi:10.1097/PAS.0b013e318215cc03
Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O et al (2008) Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 21(12):1451–1460. doi:10.1038/modpathol.2008.96
Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X et al (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17(5):443–454. doi:10.1016/j.ccr.2010.03.018
Acknowledgments
LZ and TAB drafted the manuscript. TAB supervised and oversight the manuscript outline.
Funding
This work was supported in part by the Prostate Cancer Foundation Young Investigator Award (T.A.B). This work was also supported by Prostate cancer Canada and is proudly funded by the Movember Foundation, Grant #B2013-01.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflict of interest to declare in this study.
Ethical approval
NA (review article).
Rights and permissions
About this article
Cite this article
Abou-Ouf, H., Zhao, L. & Bismar, T.A. ERG expression in prostate cancer: biological relevance and clinical implication. J Cancer Res Clin Oncol 142, 1781–1793 (2016). https://doi.org/10.1007/s00432-015-2096-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-015-2096-x